1887

Journal of General Virology header logo

Volume 92, Issue 10

Common marmoset () as a primate model of dengue virus infection: development of high levels of viraemia and demonstration of protective immunity Free

Abstract

Dengue virus (DENV) causes a wide range of illnesses in humans: dengue fever (DF), dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS). Animal models that constantly develop high levels of viraemia are required for the development of protective and preventive measures. Common marmosets () demonstrated high levels of viraemia after inoculation with clinical isolates of four serotypes of DENV; in particular, over 10 genome copies ml after inoculation with DENV-2. Non-structural protein 1 and DENV-specific IgM and IgG antibodies were consistently detected. The DENV-2 genome was detected in lymphoid organs including the lymph nodes, spleen and thymus, and also in non-lymphoid organs. DENV antigen was detected by immunohistochemistry in the liver and spleen from inoculated marmosets. Four marmosets were reinoculated with DENV-2 at 33 weeks after primary inoculation with DENV-2. The DENV-2 genome was not detected in any of these marmosets, indicating protection from a secondary infection. The results indicate that common marmosets are highly sensitive to DENV infection, and suggest that marmosets could be a reliable primate model for the evaluation of candidate vaccines.

  • Received:
  • Accepted:
  • Published Online:
© 2011 SGM
Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.031229-0
2011-10-01
2024-04-20
Loading full text...

Full text loading...

/deliver/fulltext/jgv/92/10/2272.html?itemId=/content/journal/jgv/10.1099/vir.0.031229-0&mimeType=html&fmt=ahah

References

  1. Alcon S., Talarmin A., Debruyne M., Falconar A., Deubel V., Flamand M. 2002; Enzyme-linked immunosorbent assay specific to Dengue virus type 1 nonstructural protein NS1 reveals circulation of the antigen in the blood during the acute phase of disease in patients experiencing primary or secondary infections. J Clin Microbiol 40:376–381 [View Article][PubMed]
     [Google Scholar]
  2. Balsitis S. J., Williams K. L., Lachica R., Flores D., Kyle J. L., Mehlhop E., Johnson S., Diamond M. S., Beatty P. R., Harris E. 2010; Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification. PLoS Pathog 6:e1000790 [View Article][PubMed]
     [Google Scholar]
  3. Bente D. A., Rico-Hesse R. 2006; Models of dengue virus infection. Drug Discov Today Dis Models 3:97–103 [View Article][PubMed]
     [Google Scholar]
  4. Bente D. A., Melkus M. W., Garcia J. V., Rico-Hesse R. 2005; Dengue fever in humanized NOD/SCID mice. J Virol 79:13797–13799 [View Article][PubMed]
     [Google Scholar]
  5. Bernardo L., Izquierdo A., Prado I., Rosario D., Alvarez M., Santana E., Castro J., Martínez R., Rodríguez R. et al. other authors 2008; Primary and secondary infections of Macaca fascicularis monkeys with Asian and American genotypes of dengue virus 2. Clin Vaccine Immunol 15:439–446 [View Article][PubMed]
     [Google Scholar]
  6. Bhamarapravati N., Tuchinda P., Boonyapaknavik V. 1967; Pathology of Thailand haemorrhagic fever: a study of 100 autopsy cases. Ann Trop Med Parasitol 61:500–510[PubMed]
     [Google Scholar]
  7. Blair P. J., Kochel T. J., Raviprakash K., Guevara C., Salazar M., Wu S. J., Olson J. G., Porter K. R. 2006; Evaluation of immunity and protective efficacy of a dengue-3 pre-membrane and envelope DNA vaccine in Aotus nancymae monkeys. Vaccine 24:1427–1432 [View Article][PubMed]
     [Google Scholar]
  8. de Araújo J. M., Schatzmayr H. G., de Filippis A. M., Dos Santos F. B., Cardoso M. A., Britto C., Coelho J. M., Nogueira R. M. 2009; A retrospective survey of dengue virus infection in fatal cases from an epidemic in Brazil. J Virol Methods 155:34–38 [View Article][PubMed]
     [Google Scholar]
  9. Flamand M., Megret F., Mathieu M., Lepault J., Rey F. A., Deubel V. 1999; Dengue virus type 1 nonstructural glycoprotein NS1 is secreted from mammalian cells as a soluble hexamer in a glycosylation-dependent fashion. J Virol 73:6104–6110[PubMed]
     [Google Scholar]
  10. Goncalvez A. P., Engle R. E., St Claire M., Purcell R. H., Lai C.-J. 2007; Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention. Proc Natl Acad Sci U S A 104:9422–9427 [View Article][PubMed]
     [Google Scholar]
  11. Guirakhoo F., Pugachev K., Zhang Z., Myers G., Levenbook I., Draper K., Lang J., Ocran S., Mitchell F. et al. other authors 2004; Safety and efficacy of chimeric Yellow fever-dengue virus tetravalent vaccine formulations in nonhuman primates. J Virol 78:4761–4775 [View Article][PubMed]
     [Google Scholar]
  12. Halstead S. B. 2007; Dengue. Lancet 370:1644–1652 [View Article][PubMed]
     [Google Scholar]
  13. Ito M., Takasaki T., Yamada K., Nerome R., Tajima S., Kurane I. 2004; Development and evaluation of fluorogenic TaqMan reverse transcriptase PCR assays for detection of dengue virus types 1 to 4. J Clin Microbiol 42:5935–5937 [View Article][PubMed]
     [Google Scholar]
  14. Ito M., Mukai R. Z., Takasaki T., Kotaki A., Kurane I. 2010; Antibody-dependent enhancement of dengue virus infection in vitro by undiluted sera from monkeys infected with heterotypic dengue virus. Arch Virol 155:1617–1624 [View Article][PubMed]
     [Google Scholar]
  15. Jessie K., Fong M. Y., Devi S., Lam S. K., Wong K. T. 2004; Localization of dengue virus in naturally infected human tissues, by immunohistochemistry and in situ hybridization. J Infect Dis 189:1411–1418 [View Article][PubMed]
     [Google Scholar]
  16. Koraka P., Benton S., van Amerongen G., Stittelaar K. J., Osterhaus A. D. 2007; Efficacy of a live attenuated tetravalent candidate dengue vaccine in naïve and previously infected cynomolgus macaques. Vaccine 25:5409–5416 [View Article][PubMed]
     [Google Scholar]
  17. Libraty D. H., Endy T. P., Houng H. S., Green S., Kalayanarooj S., Suntayakorn S., Chansiriwongs W., Vaughn D. W., Nisalak A. et al. other authors 2002a; Differing influences of virus burden and immune activation on disease severity in secondary dengue-3 virus infections. J Infect Dis 185:1213–1221 [View Article][PubMed]
     [Google Scholar]
  18. Libraty D. H., Young P. R., Pickering D., Endy T. P., Kalayanarooj S., Green S., Vaughn D. W., Nisalak A., Ennis F. A., Rothman A. L. 2002b; High circulating levels of the dengue virus nonstructural protein NS1 early in dengue illness correlate with the development of dengue hemorrhagic fever. J Infect Dis 186:1165–1168 [View Article][PubMed]
     [Google Scholar]
  19. Mackenzie J. M., Jones M. K., Young P. R. 1996; Immunolocalization of the dengue virus nonstructural glycoprotein NS1 suggests a role in viral RNA replication. Virology 220:232–240 [View Article][PubMed]
     [Google Scholar]
  20. Marchette N. J., Halstead S. B. Jr, Falkler W. A. Jr, Stenhouse A., Nash D. 1973; Studies on the pathogenesis of dengue infection in monkeys. 3. Sequential distribution of virus in primary and heterologous infections. J Infect Dis 128:23–30 [View Article][PubMed]
     [Google Scholar]
  21. Mizuno Y., Kotaki A., Harada F., Tajima S., Kurane I., Takasaki T. 2007; Confirmation of dengue virus infection by detection of dengue virus type 1 genome in urine and saliva but not in plasma. Trans R Soc Trop Med Hyg 101:738–739 [View Article][PubMed]
     [Google Scholar]
  22. Moi M. L., Takasaki T., Kotaki A., Tajima S., Lim C. K., Sakamoto M., Iwagoe H., Kobayashi K., Kurane I. 2010a; Importation of dengue virus type 3 to Japan from Tanzania and Cote d’Ivoire. Emerg Infect Dis 16:1770–1772[PubMed] [CrossRef]
     [Google Scholar]
  23. Moi M. L., Lim C. K., Kotaki A., Takasaki T., Kurane I. 2010b; Discrepancy in dengue virus neutralizing antibody titers between plaque reduction neutralizing tests with Fcγ receptor (FcγR)-negative and FcγR-expressing BHK-21 cells. Clin Vaccine Immunol 17:402–407 [View Article][PubMed]
     [Google Scholar]
  24. Onlamoon N., Noisakran S., Hsiao H. M., Duncan A., Villinger F., Ansari A. A., Perng G. C. 2010; Dengue virus-induced hemorrhage in a nonhuman primate model. Blood 115:1823–1834 [View Article][PubMed]
     [Google Scholar]
  25. Poloni T. R., Oliveira A. S., Alfonso H. L., Galvão L. R., Amarilla A. A., Poloni D. F., Figueiredo L. T., Aquino V. H. 2010; Detection of dengue virus in saliva and urine by real time RT-PCR. Virol J 7:22 [View Article][PubMed]
     [Google Scholar]
  26. Raviprakash K., Wang D., Ewing D., Holman D. H., Block K., Woraratanadharm J., Chen L., Hayes C., Dong J. Y., Porter K. 2008; A tetravalent dengue vaccine based on a complex adenovirus vector provides significant protection in rhesus monkeys against all four serotypes of dengue virus. J Virol 82:6927–6934 [View Article][PubMed]
     [Google Scholar]
  27. Rosen L., Drouet M. T., Deubel V. 1999; Detection of dengue virus RNA by reverse transcription-polymerase chain reaction in the liver and lymphoid organs but not in the brain in fatal human infection. Am J Trop Med Hyg 61:720–724[PubMed]
     [Google Scholar]
  28. Schiavetta A. M., Harre J. G., Wagner E., Simmons M., Raviprakash K. 2003; Variable susceptibility of the owl monkey (Aotus nancymae) to four serotypes of dengue virus. Contemp Top Lab Anim Sci 42:12–20[PubMed]
     [Google Scholar]
  29. Shrestha B., Brien J. D., Sukupolvi-Petty S., Austin S. K., Edeling M. A., Kim T., O’Brien K. M., Nelson C. A., Johnson S. et al. other authors 2010; The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1. PLoS Pathog 6:e1000823 [View Article][PubMed]
     [Google Scholar]
  30. Vaughn D. W., Green S., Kalayanarooj S., Innis B. L., Nimmannitya S., Suntayakorn S., Rothman A. L., Ennis F. A., Nisalak A. 1997; Dengue in the early febrile phase: viremia and antibody responses. J Infect Dis 176:322–330 [View Article][PubMed]
     [Google Scholar]
  31. Whitehead S. S., Hanley K. A. Jr, Blaney J. E. Jr, Gilmore L. E., Elkins W. R., Murphy B. R. 2003; Substitution of the structural genes of dengue virus type 4 with those of type 2 results in chimeric vaccine candidates which are attenuated for mosquitoes, mice, and rhesus monkeys. Vaccine 21:4307–4316 [View Article][PubMed]
     [Google Scholar]
  32. WHO 2002; Dengue and dengue haemorrhagic fever. Fact sheet no. 117
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.031229-0
Loading
Common marmoset (Callithrix jacchus) as a primate model of dengue virus infection: development of high levels of viraemia and demonstration of protective immunity
J. Gen. Virol. 92, 2272 (2011); https://doi.org/10.1099/vir.0.031229-0
/content/journal/jgv/10.1099/vir.0.031229-0
/content/journal/jgv/10.1099/vir.0.031229-0
Loading

Data & Media loading...

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error